Where Will Merrimack Pharmaceuticals Inc (MACK) Stock Go Next After It Is Up 12.40% in a Week?

The market has been high on Merrimack Pharmaceuticals Inc (MACK) stock recently. MACK gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Merrimack Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MACK!

See Full MACK Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With MACK Stock Today?

Merrimack Pharmaceuticals Inc (MACK) stock is down -2.13% while the S&P 500 has gained 0.32% as of 12:29 PM on Wednesday, Feb 14. MACK is down -$0.32 from the previous closing price of $15.00 on volume of 461,137 shares. Over the past year the S&P 500 is up 20.11% while MACK has gained 24.20%. MACK lost -$0.10 per share in the over the last 12 months. To screen for more stocks like Merrimack Pharmaceuticals Inc click here.

More About Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products. Click Here to get the full Stock Report for Merrimack Pharmaceuticals Inc stock.